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QUALITY ASSESSMENT OF CLINICAL PRACTICE GUIDELINES IN EMERGENCY MEDICINE
Alyssa Zupon, Ting-Xu Tan, Gina Siddiqui, Katherine Couturier, Matthew James, Craig Rothenberg, Arjun
Venkatesh. Department of Emergency Medicine, Yale University School of Medicine, New Haven, CT.
Clinical practice guidelines (CPGs) have been published by the American College of Emergency
Physicians (ACEP) since 1990 to advance the delivery of emergency medical care. These guidelines have
raised controversy, and recent research shows that they are largely based on lower classes of evidence and
expert opinion despite Institute of Medicine recommendations. The rigor of development and overall
quality of these guidelines have not yet been assessed. Thus, we performed a systematic review and metaanalysis to evaluate the quality of ACEP Clinical Policies using a recognized, validated appraisal
instrument: Appraisal of Guideline for Research & Evaluation (AGREE II).
The AGREE II instrument contains 23 appraisal items (scored on a 1 - 7 scale) in six quality domains and
two overall assessments. The domains are Scope and Purpose, Stakeholder Involvement, Rigor of
Development, Clarity of Presentation, Applicability, and Editorial Independence. Appraisals were
performed independently and in random order by five trained appraisers. Primary outcomes were AGREE
II ratings for each item, domain, and Overall Assessment. Domain and Overall Assessment ratings were
standardized for analyses. Secondary analyses examined associations between AGREE II ratings and date
of publication, strength of underlying evidence, and strength of recommendations. Additional analysis
examined relationships between domain and Overall Assessment ratings.
Twenty guidelines published from October 2008 to November 2017 were included. Of the six domains,
Scope and Purpose scored highest and varied least (mean 90%, coefficient of variation (CV) 0.03), while
Applicability scored lowest and varied most (mean 35%, CV 0.16). The four remaining domains had mean
scores of 53% - 78% and CVs of 0.3 - 0.14. The mean Overall Assessment rating was 69% (CV 0.13) and
was not associated with CPG publication date, strength of underlying evidence, or strength of
recommendations. Statistically significant relationships were found between Overall Assessment ratings
and two domains (Rigor of Development and Clarity of Presentation).
Based on validated criteria, ACEP Clinical Policies have identifiable areas of strength and weakness. The
overall CPG quality did not improve over time and is not explained by the quality of underlying evidence.
ACEP Clinical Policies can be improved by including patient representation in the guideline development
process and addressing factors that influence the application of these guidelines in clinical practice.
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Introduction
Background
The explosion of medical literature in recent decades has provided increased
access to evidence that can improve health care delivery, yet the volume of available
resources can be overwhelming, the quality of the literature uncertain, and the
consistency of information incongruous (1-3). Particularly in an era of digitized and
electronic resources and libraries, it is possible to quickly disseminate vast quantities of
information without standardized organization or curation of that content, thereby
limiting translation into practice. Indeed, the Institute of Medicine’s (IOM) 2001 report
“Crossing the Quality Chasm: A New Health System for the 21st Century” identified
significant gaps between best-available evidence and medical practice (4).
In an effort to close these gaps, clinical practice guidelines (CPGs) were
developed to provide synthesized and critically appraised evidence to enhance clinician
and patient decision-making. CPGs aim to translate the complexity of scientific research
findings into clinical recommendations and advance the quality of health care delivery
through acceleration of knowledge translation, promotion of cost-effective practices, and
reduction of practice variation (5). Further, CPGs can influence the development of
educational programs, quality measures, and research agendas (6).
Literature review
In the past three decades, there has been a notable increase in the publication and
use of CPGs among various medical specialty societies, health care institutions, and
governmental bodies (5, 7). In 1989, there were an estimated 700 available guidelines,
and, in 2017, there are over 6,400 guidelines from 79 countries listed in the Guidelines
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International Network database (1, 8). This increase in the number of guidelines, however,
has raised concern about the lack of standardization in the development process and
information presentation. Studies have shown that the recommendations provided in
various CPGs can be conflicting (9, 10) and the information can be invalid, unreliable, or
irrelevant to clinical practice (3, 11). Further, low quality CPGs have the potential to
undermine the credibility of more valid guidelines and lead to patient harm if incorrect
recommendations were implemented into practice (3, 9, 10). A prior review on the
quality of guidelines produced in the 1990s showed that, out of 431 CPGs, 67% did not
describe the individuals involved with guideline development, 88% did not report how
evidence was identified, and 82% did not indicate the strength of recommendations (3,
11).
Concerns about the low quality and high variability of CPGs motivated the
development of several initiatives to formalize methods for guideline appraisal. Most
notably is the Appraisal of Guidelines for Research and Evaluation (AGREE)
Collaboration, established in 1998 by an international group of researchers from 13
countries (12). In 2003, this group developed the original AGREE instrument, which
provided a systematic framework for assessing the methodological rigor, transparency of
development, and quality of reporting in CPGs. The AGREE instrument has been
translated into numerous languages, is the only appraisal tool that has been validated
internationally, and has been formally endorsed by several organizations such as the
World Health Organization Advisory Committee on Health Research (3, 12, 13). The
instrument underwent revision in 2010, and the new AGREE II instrument has since been
cited in over 650 publications (14).
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Shortly after the release of the AGREE II instrument, the IOM also published its
own report aimed to outline objective, scientifically valid, and consistent approaches to
developing practice guidelines (5, 16). This 2011 report, “Clinical Practice Guidelines
We Can Trust,” provided eight standards of guideline trustworthiness that are similar in
content and structure to the AGREE II criteria (5, 12, 16, 17). Both the AGREE II
instrument and IOM’s standards of trustworthiness have been widely applied in efforts to
advance the quality and appropriate utilization of clinical practice guidelines (17- 27).
Among the many medical specialties promulgating CPGs is emergency medicine.
Given the broad nature of emergency medical care, policies outlining standardized
approaches can have substantial effect on patient outcomes by promoting evidence-based
acute diagnostics and treatments, reducing practice variation, and limiting unnecessary
costs and interventions. Emergency physicians have also identified CPGs as essential to
providing synthesized, curated content and reassurance of legal protection (28, 29).
Guidelines specifically for emergency medical care were first published by the American
College of Emergency Physicians (ACEP) in 1990. The first guideline focused on nontraumatic chest pain and presented a general approach to undifferentiated disease,
focusing on key aspects of the history and physical exam (1). Since then, the ACEP
Clinical Policies Committee was formed and a formal methodology was adopted in
parallel with the growing popularity and prominence of evidence-based medicine. Since
1998, ACEP has been publishing evidence-based, peer-reviewed guidelines structured to
answer specific, clinically relevant questions considered to be of high frequency or high
risk in emergency medicine (1, 2).
Despite the positive effect that ACEP Clinical Policies have on the delivery of
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emergency care (19), they have also been a target for scrutiny and a source of controversy.
ACEP’s 2013 Clinical Policy on intravenous tissue plasminogen activator (tPA) use in
acute ischemic stroke was met with skepticism by emergency physicians who felt that the
recommendations lacked both adequate supporting evidence and consideration of the
adverse outcomes of treatment (17, 28). Three out of eight panelists who developed this
Clinical Policy disclosed relevant industry relationships, yet seven had affiliations with
the Foundation for Education and Research in Neurological Emergencies, which received
all of its donations from drug companies, including alteplase manufacturer, Genentech
(17). This concern about industry influence resulted in not only revision of the
guideline’s recommendations but also substantial reevaluation of ACEP’s Clinical Policy
development process, rating methodology, and management of conflicts of interest (30).
This methodological update was applied to the revised version of the Clinical Policy on
tPA use, published in September 2015, and all policies published since. Another recent
analysis of ACEP’s Clinical Policies revealed that the majority of clinical
recommendations are based on lower classes of evidence or expert opinion as opposed to
higher classes of evidence such as controlled clinical trials (6). To date, there has been no
formal appraisal of ACEP’s Clinical Policies to evaluate their quality based on validated
criteria.
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Statement of Purpose
Accordingly, we sought to assess the methodological rigor, transparency of
development, and overall quality of current ACEP Clinical Policies using the AGREE II
appraisal instrument. Secondarily, we sought to examine whether AGREE II ratings
reflected improvement in Clinical Policies’ quality over time and, specifically, after
ACEP methodological updates in 2015. We also evaluated whether certain aspects of
CPG quality were related to the CPG’s overall quality assessment. Finally, we examined
whether there were associations between AGREE II ratings and the strength of
underlying evidence or recommendations in these CPGs.
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Methods
Overview of thesis responsibilities
AZ and AV established the purpose and scope of this thesis project. AZ
developed the draft data collection tool and study protocol with supervision by AV. AZ
utilized the AGREE II instrument to assess all ACEP Clinical Policies in this study. To
meet recommendations made by AGREE II developers, the project was expanded to
include additional review by emergency medicine residents (TT, GS, KC, MJ). AZ, AV,
and CR analyzed and interpreted the data. AZ primarily drafted the manuscript with
critical review and revision by CR and AV.

Study design
Systematic review of American College of Emergency Physicians Clinical
Policies using the AGREE II appraisal instrument (32, 33).
Selection of clinical practice guidelines
We included all American College of Emergency Physician (ACEP) Clinical
Policies listed as “current” as of May 24, 2017, from the ACEP Clinical & Practice
Management website, http://www.acep.org/clinicalpolicies/. During data collection, one
Clinical Policy was replaced with a revised version ("Emergency Department
Management of Patients Needing Reperfusion Therapy for an ST-Segment Elevation
Acute Myocardial Infarction”) and thus our study included the revised policy and
excluded the prior version. Also, after data collection, one Clinical Policy ("Critical
Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency
Department with Syncope”) was removed from the “current” list but remained in this
study, as it was current at the time of initial guideline selection. Each Clinical Policy is
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comprised of a peer-reviewed manuscript with evidence-based recommendations aimed
to guide clinical decision-making. All Clinical Policies are authored by ACEP and follow
the ACEP Clinical Policy development process, which includes expert review from
medical specialists and societies relevant to the policy topic. These outside participants’
affiliations are noted in each Clinical Policy, and their involvement does not imply
endorsement of the policy. ACEP Clinical Policies are specific to emergency care in the
United States, are regularly published and maintained, and are sponsored by ACEP (6).
While other professional organizations publish guidelines for, or relevant to, emergency
care, few other groups have a regular process or a committee responsible for guideline
maintenance. This study did not include clinical practice guidelines either published by
other professional organizations in emergency medicine or primarily authored by other
organizations and co-signed or endorsed by ACEP.
Data abstraction
The AGREE II instrument
The data were abstracted using the electronic web tool created by the AGREE II
developers, available at http://www.agreetrust.org/. This instrument consists of 23 key
items organized within six quality domains and two additional global assessments. Each
item is rated on a Likert scale between 1 (strongly disagree) and 7 (strongly agree). Each
domain captures a unique dimension of guideline quality, specifically Scope and Purpose,
Stakeholder Involvement, Rigor of Development, Clarity of Presentation, Applicability,
and Editorial Independence.
Scope and Purpose is concerned with the overall aim of the guideline, the specific
health questions, and the target population.
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Stakeholder Involvement focuses on the extent to which the guideline
development group includes individuals from all relevant professional groups, represents
the views of its intended users, and clearly defines its target population.
Rigor of Development relates to the process utilized to gather and synthesize the
evidence, the methods utilized to formulate the recommendations, and the criteria used to
update them. Specifically, the items in this domain evaluate whether systematic methods
were used to search for evidence, criteria for selecting the evidence are clearly described,
the strengths and limitations of the body of evidence are identified, the methods for
formulating the recommendations are clear, the risks and benefits have been considered,
there is an explicit link between the recommendations and the supporting evidence, the
guideline has been externally reviewed by experts prior to its publication, and a
procedure for updating the guideline is provided.
Clarity of Presentation addresses the language, structure, and format of the
guideline, specifically whether the recommendations are specific and unambiguous, other
options for management are presented, and key recommendations are easily identifiable.
Applicability pertains to factors affecting guideline implementation, strategies to
improve uptake, and resource implications of applying the recommendations in practice.
These items evaluate whether the guideline describes facilitators and barriers to its
application, advice or tools on how the recommendations can be put into practice,
potential resource implications of applying the recommendation, and monitoring and/or
auditing criteria.

9
Editorial Independence is concerned with whether the views of the funding body
have influenced the content of the guideline and whether competing interests of guideline
group members have been recorded and addressed.
After completing assessments for the six domains, the instrument prompts the
reviewer for an overall assessment of the guideline (using the same 1 to 7 Likert scale)
and a categorical recommendation for use in clinical practice (“yes,” “yes with
modification,” or “no”). These two global assessments are based on the reviewer’s
overall impression of the guideline and are not calculated from item or domain ratings. A
full description of each quality domain, 23 items, and global assessments is provided in
Appendix I.
Sample data abstraction
An example of an individual review of a clinical practice guideline using the
AGREE II instrument is provided below (completed by reviewer AZ). Each of the 23
items within the six domains is listed with its associated annotation and reason for rating.

Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the
Emergency Department Using the AGREE II Instrument
1. Scope and Purpose
1. The overall objective(s) of the guideline is (are) specifically described.
Rating: 6
Page 481, column 1. This clinical policy from ACEP addresses key issues for the
diagnosis and management of adult psychiatric patients in the emergency
department. A writing subcommittee conducted a systematic review of literature
to derive evidence-based recommendations to answer the following clinical
questions. The four clinical questions are clearly delineated.
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2. The health question(s) covered by the guideline is (are) specifically described.
Rating: 7
The guideline presents four "critical questions" (pages 483-487) in a very clear
manner. Further, based on the definition provided and the discussion of each
critical question, the context of the critical question relative to overall clinical
practice is provided.

3. The population (patients, public, etc.) to whom the guideline is meant to
apply is specifically described.
Rating: 7
Page 483, column 1. Inclusion Criteria: This guideline applies to adult patients
presenting to the ED with psychiatric symptoms.
Critical Question 4 includes patients with delirium.
Exclusion Criteria: This guideline is not intended to be used for pediatric patients.
Also not intended for patients with delirium in regard to Critical Questions 1, 2, 3.

2. Stakeholder Involvement
4. The guideline development group includes individuals from all relevant
professional groups.
Rating: 5
Page 482, column 1. This policy is a product of the ACEP Clinical Policy
development process, including expert review. Expert review comments were
received from emergency physicians, psychiatrists, members of the American
Association for Emergency Psychiatry, the American Association of Community
Psychiatrists, and ACEP's Medical Legal committee. Comments were received
during a 60-day open-comment period, with notices of the comment period sent in
an email to ACEP members, published in EM Today, and posted on the ACEP
Web site. The responses were used to further refine and enhance the policy;
however, they do not imply endorsement of this clinical policy. Lacks details of
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how input from these institutions, members, or experts was used by the guideline
development group.

5. The views and preferences of the target population (patients, public, etc.)
have been sought.
Rating: 2
No mention of seeking outside opinion (public, patient, etc.) was noted in the
guideline. They do reference in the Intro (page 481) how ED are taking the
weight of the substantial decline in mental health resource allocation for patients
with mental health issues, but no proposal for how to get additional stakeholders
involved.

6. The target users of the guideline are clearly defined.
Rating: 7
Page 483, column 1. Scope of Application: This guideline is intended for
physicians working in EDs.

3. Rigor of Development
7. Systematic methods were used to search for evidence.
Rating: 6
Page 482, column 1. This Clinical Policy was created after careful review and
critical analysis of medical literature and was based on a systematic review of the
literature. Searches of MEDLINE, MEDLINE InProcess, Scopus, Web of Science,
and the Cochrane Database were performed. All searches were limited to
English-language sources, adults, and human studies. Specific key words/phrases,
years used in the searches, dates of searches, and study selection were identified
under each critical question. In addition, relevant articles from the bibliographies
of included studies and more recent articles identified by committee members and
reviewers were included.

8. The criteria for selecting the evidence are clearly described.
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Rating: 6
Page 482, column 1. As noted in Item 7. Additionally, the evidence was graded
(page 482, column 1) and assigned a class (Class I, II, III) based on a
predetermined process taking into account design and quality of study –
("Assessment of Classes of Evidence” – Appendix A, Appendix B and evidentiary
table) for use in making the recommendation. The guideline describes the
translation of evidence class for making the recommendation (Level A, B, C)
(page 482, column 2).

9. The strengths and limitations of the body of evidence are clearly described.
Rating: 6
Strengths and Limitations are mentioned. Examples: Page 482, column 1. All
searches were limited to English-language sources, adults and human studies.
Page 482, column 1. When literature was not available, consensus of emergency
physicians was used. Page 482, column 2. There are certain circumstances in
which the recommendation stemming from a body of evidence should not be rated
as highly as the individual studies on which they are based. Page 483, column 1.
This policy is not intended to be a complete manual on the diagnosis and
management of adult psychiatric patients in the ED. Page 483, column 2. This
policy is not intended to represent a legal standard of care for emergency
physicians. Page 483, column 2. Recommendations not intended to represent the
only diagnostic or management options. The guideline defines for the physician
those strategies for which medical literature exist to provide support for answers
to the critical questions addressed in this policy. Page 483, column 2. For
potential benefits and harms of implementing the recommendations, see Appendix
D. Page 486, column 2. This clinical policy demonstrates that there is no tool
currently available that can be solely used to predict the risk of suicide among
patient in the ED.

10. The methods for formulating the recommendations are clearly described.
Rating: 7
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Methodology (page 482). Provides a detailed description of the methodology used,
the review process, the citations by years, etc. There was a thorough assessment
of the literature and the evidence was graded and assigned a grade (Class I, II,
III) based on predetermined process taking into account design and quality of
study (Appendix A and B, Evidentiary Table) for use in making the
recommendation (Level A, B, C). For the Critical Questions (pages 483-487)
there are logical discussions of the problems and literature leading up to a clear
and concise "recommendation" for each of the four critical questions.

11. The health benefits, side effects, and risks have been considered in
formulating the recommendations.
Rating: 6
For potential benefits and harms of implementation the recommendation, the
guideline provides Appendix D. This appendix uses the same format as the critical
questions and recommendation, and provides a review of benefit/harm associated
with the recommendations. More details could be provided.

12. There is an explicit link between the recommendations and the supporting
evidence.
Rating: 7
The four Critical Questions (pages 483-487) addressed in the guideline are
clearly delineated and clinical practice recommendations are provided. Research
supporting the recommendation is well described. Further, the recommendations
are assigned a level (Level A, B, C) based on the strength of evidence (Class I, II,
III) and expert opinion (Assessment of Classes of Evidence and Translation of
Classes of Evidence to Recommendation Levels) (page 482, column 2).
Additionally, inclusion of "future research" for each of the critical questions
(page 484, column 1) provides additional insight into the current evidence
supporting the clinical recommendation.
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13. The guideline has been externally reviewed by experts prior to its
publication.
Rating: 5
Page 482, column 1. This policy is a product of the ACEP Clinical Policy
development process, including expert review. Expert review comments were
received from emergency physicians, psychiatrists, members of the American
Association for Emergency Psychiatry, the American Association of Community
Psychiatrists, and ACEP's Medical Legal committee. Comments were received
during a 60-day open-comment period, with notices of the comment period sent in
an email to ACEP members, published in EM Today, and posted on the ACEP
Web site. The responses were used to further refine and enhance this policy;
however, they do not imply endorsement of this clinical policy. Lacks detailed
description of reviewers, outcome and summary of key findings, and description
of how/whether information was used in the guideline.

14. A procedure for updating the guideline is provided.
Rating: 5
Page 482, column 1. Clinical policies are scheduled for review and considered
for revision every 3 years, however, interim reviews are conducted when
technology, methodology or the practice environment changes significantly. No
definition/explanation of what "significantly" means.

4. Clarity of Presentation
15. The recommendations are specific and unambiguous.
Rating: 5
Critical Questions, pages 483-487. While the critical questions are clearly
delineated, they are occasionally vague, and given the nature of the patients being
treated (psychiatric patients) there are provided a range of management
strategies. But in general, by grading the level of evidence (Class I, II, III) and
using that grading in establishing the recommendation (Level A, B, C) the
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guideline provides the ED physician with a level of confidence on how to interpret
the recommendation, which is helpful.

16. The different options for management of the condition or health issue are
clearly presented.
Rating: 5
Each critical question (pages 483-487) is clearly defined, and research
supporting the recommendation delineated. In these discussions, they provide
clinical background and alternate choices. For example, Page 484, column 1.
Existing literature indicates that routine or ancillary laboratory testing for
psychiatric patients has little or no use in ED. It is likely that subsets of patients
with higher rates of disease (e.g., elderly, immunosuppressed, new onset
psychosis, substance abuse) may benefit from routine laboratory testing. Although
urine toxicology screen has no benefit for management or disposition of the
patient in the ED, it may be helpful to obtain an objective understanding of the
patient’s potential substance abuse on transfer to a psychiatric facility.

17. Key recommendations are easily identifiable.
Rating: 7
The critical questions addressed in the guideline (pages 483-487) are clearly
delineated and clinical practice recommendations are provided. Further the
recommendations are assigned a level (Level A, B, C) based on the strength of
evidence (Class I, II, III) and expert opinion (page 482).

5. Applicability
18. The guideline describes facilitators and barriers to its application.
Rating: 4
Overall does not identify facilitators and barriers to application, but makes some
comments about application. For example, Page 484, column 1: To expedite the
care of patients, agreement between the ED and local psychiatric facilities
regarding minimal laboratory testing for psychiatric clearance should be
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mutually determined. Page 485, column 1: Given that many acutely psychiatric
patients may not be able to cooperate with a comprehensive neurological
examination, emergency physicians may have a lower threshold to obtain
neuroimaging in these patients. Page 486, column 2: This clinical policy review
demonstrates that there is no tool currently available that can be solely used to
predict the risk of suicide among patients in the ED who have suicidal ideation.

19. The guideline provides advice and/or tools on how the recommendations
can be put into practice.
Rating: 2
The guideline does not address this explicitly. However, since the guideline is
provided by ACEP to all members and published in Annals of Emergency
Medicine, mere dissemination of the guideline promotes its use. The format of the
guideline, by clearly identifying critical questions and then providing
recommendations, facilitates use of the guideline.

20. The potential resource implications of applying the recommendations have
been considered.
Rating: 2
Resource implications for applying the guidelines were not explicitly addressed.
However, in the evaluations and eventual recommendations (pages 483-487) it
mentions trying to optimize testing and emergency department time and still
provide optimal care.

21. The guideline presents monitoring and/or auditing criteria.
Rating: 2
The guideline does not specifically address monitoring/auditing.

6. Editorial Independence
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22. The views of the funding body have not influenced the content of the
guideline.
Rating: 5
Page 482, column 1. ACEP was the funding source for this ACEP clinical policy.
The members of the ACEP policies committee could thus have an influence on this
final guideline. This may be minor, but there is an opening for influence.

23. Competing interests of guideline development group members have been
recorded and addressed.
Rating: 5
Page 487, column 2. There were no relevant industry relationships disclosed by
the subcommittee members for this topic. Relevant industry relationships are
those relationships with companies associated with products or services that
significantly impact the specific aspect of disease addressed in the critical
questions. Would be more complete if all relationships the authors have both
financially and academically were reported.

Overall Assessment
Overall Quality of This Guideline: 5/7
Guideline Recommended for Use? Yes.

Group appraisal process
Data abstraction was designed to meet or exceed guidance of the AGREE II
instrument developers. The AGREE II developers recommend a minimum of two
appraisers and optimally four appraisers for stable estimates of CPG quality. In our study,
all twenty ACEP Clinical Policies were reviewed by five appraisers (AZ, TT, GS, KC,
and MJ). Prior to data abstraction, each appraiser completed a standardized online
training module specifically for use of AGREE II (12, 34), and a group session was

18
conducted after reviewing the first three guidelines to ensure consistent use of definitions.
All appraisals were performed independently between May 2017 and September 2017.
Further, each appraiser was assigned a unique and random order to perform the data
abstraction to minimize bias due to increased familiarity with the instrument over time.
Data abstraction for underlying evidence and recommendations
Each Clinical Policy contains clinical recommendations based on medical
literature to address critical questions faced by emergency physicians. For each
recommendation found in a Clinical Policy, we recorded the proportion of
recommendations that were Level C (the weakest level of recommendation). Level C
recommendations are based on evidence from Design Class III studies or expert
consensus. We also recorded the proportion of references within each Clinical Policy that
were graded as Design Class III evidence. Studies considered as Class III evidence are
case series, case reports, and consensus or review papers.
Outcomes
The primary outcomes were AGREE II ratings for each item, each domain,
Overall Assessment, and recommendation for use in clinical practice.
Analysis
Primary analysis
For the primary descriptive analysis, domain and Overall Assessment ratings were
standardized as a percentage according to the following formula recommended by
AGREE II developers (32):
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(Obtained score – Minimum possible score) / (Maximum possible score – Minimum
possible score) x 100
Ratings were calculated at the domain level and not at the item level. Using the
example assessment above, the domain of Stakeholder Involvement is comprised of three
items (items 4, 5, and 6) with item scores of 5, 2, and 7, respectively. The maximum
score for this three-item domain is 21 (3 x 7) and the minimum score is 3 (3 x 1). The
obtained score from the above example was 14 (5 + 2 + 7). Thus, this domain’s
standardized score was 61%, calculated by (14 - 3) / (21 – 3) x 100.
The standardized score using this formula was determined for each domain and
Overall Assessment for each reviewer. The standardized percentages from all five
reviewers were then reported as the mean, standard deviation, coefficient of variation,
and range.
Secondary analysis
Secondary analyses were performed to further assess ACEP Clinical Policies.
First, we examined whether AGREE II domain and Overall Assessment ratings changed
over the ten-year span (2007-2017) that the Clinical Policies were published. We further
evaluated AGREE II ratings before and after the ACEP Clinical Policy methodology was
updated in September 2015 using t-tests for each domain and Overall Assessment.
Second, we evaluated for any relationship between each domain rating and Overall
Assessment rating by calculating correlation coefficients between each domain and the
Overall Assessment rating. Third, we examined the association between AGREE II
ratings and the strengths of the CPGs’ underlying evidence and recommendations. We
report correlation coefficients between AGREE II Overall Assessment ratings and 1) the
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proportion of Class III evidence within an ACEP Clinical Policy and 2) the proportion of
Level C recommendations within an ACEP Clinical Policy. These measures have been
previously utilized to describe the strength of emergency medicine clinical practice
guidelines (6).
In addition, to examine inter-rater reliability between the five appraisers, we
calculated intra-class coefficients (ICC) for each of the six quality domains. This
approach is consistent with prior studies utilizing the AGREE II instrument. For all
analysis, we considered alpha equal to or less than 0.05 to be statistically significant and
we accounted for multiple comparisons using the Bonferroni correction where
appropriate (35). Data analysis was performed using R statistical software (version 3.4.2).
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Results
Data set description
This study included twenty clinical practice guidelines published by ACEP
between April 2007 and November 2017. Of all included guidelines, 13 were published
prior to methodological updates in September 2015 and seven (35%, ACEP 1- 6 and
ACEP 20) were published after the update (Table I).
Results of primary analysis
The mean results from the standardized scores of all five reviewers are provided
in Table II. The results for the primary analysis rated by this author (AZ) using the
standardized scoring formula can be found in Appendix II.
Of the six AGREE II domains, Scope and Purpose had the highest mean rating
and the lowest variability (mean rating 90%, coefficient of variation (CV) of 0.03, range
84 – 96%). Applicability had the lowest mean rating and highest variability (mean rating
35%, CV of 0.16, range 37 - 77%). The four remaining domains, from highest to lowest
rating, were Rigor of Development (mean rating 78%, CV of 0.03, range 73 – 83%),
Clarity of Presentation (mean rating 75%, CV of 0.07, range 59 – 82%), Editorial
Independence (mean rating 68%, CV of 0.13, range 37 – 77%), and Stakeholder
Involvement (mean rating 53%, CV of 0.08, range 46 – 63%).
For the Overall Assessment, the mean rating for all twenty CPGs from the five
appraisers was 69% with CV of 0.13 and a range from 50% to 83% (Table II). The three
Clinical Policies with the highest mean Overall Assessments ratings were “Neuroimaging
and Decisionmaking in Adult Mild Traumatic Brain Injury in the Acute Setting” (83%),
“Emergency Department Management of Patients Needing Reperfusion Therapy for an
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ST-Segment Elevation Acute Myocardial Infarction” (80%), and "Clinical Policy for
Well-Appearing Infants and Children Younger Than 2 Years of Age Presenting to the
Emergency Department With Fever” (80%). The three Clinical Policies with the lowest
mean Overall Assessment ratings were “Critical Issues in the Evaluation and
Management of Emergency Department Patients With Suspected Appendicitis” (50%),
“Critical Issues in the Evaluation and Management of Adult Patients in the Emergency
Department with Asymptomatic Elevated Blood Pressure” (50%), and “Clinical Issues in
the Prescribing of Opioids for Adult Patients in the Emergency Department” (53%).
Regarding whether the five appraisers recommended these guidelines for clinical
use, the vast majority of responses were “yes” or “yes with modifications” (Table III).
There were, however, “no” responses for Clinical Policies on asymptomatic elevated
blood pressure (two “no” recommendations), prescribing opioids for adult patients (two
“no” recommendations), suspected appendicitis (one “no” recommendation), and acute
carbon monoxide poisoning (one “no” recommendation). These four clinical policies
also had the four lowest mean Overall Assessment ratings of all Clinical Policies in this
study (50%, 53%, 50% and 63%, respectively). There was low inter-rater reliability with
ICC values ranging from 0.01 to 0.07.
Results of secondary analysis
There was no significant relationship between Overall Assessment rating and date
of CPG publication (Figure 1). Further, there was no significant improvement in the
Overall Assessment ratings or in any of the six domains after updates to ACEP guideline
development process in September 2015 (Table IV).
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Of the six domains, Rigor of Development and Clarity of Presentation had the
strongest association with the Overall Assessment rating (R = 0.70, p < 0.001; R = 0.77, p
< 0.0001, respectively) (Table V). The other four domains’ ratings were not strongly
associated with Overall Assessment rating (R: 0.01 - 0.51).
The listing of recommendation level, class of evidence, and Overall Assessment
rating for each Clinical Policy is shown in Table VIa and VIb. No significant correlation
was evident between Overall Assessment and either the proportion of Level C
recommendations (R= 0.06, p = 0.96) (Figure 2a) or proportion of Class III evidence (R=
0.01, p = 0.79) (Figure 2b).
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Discussion
Study summary
Overall, ACEP Clinical Policies rated highly based on the validated AGREE II
instrument of CPG quality. There was, however, variability in the quality of ACEP
Clinical Policies based on AGREE II domains, with strengths primarily in Scope and
Purpose, Rigor of Development, and Clarity of Presentation; weakness in Applicability;
and mixed results in Stakeholder Involvement and Editorial Independence. There were no
significant improvements in any domain or Overall Assessment ratings over time. The
domains of Rigor of Development and Clarity of Presentation were most strongly
associated with Overall Assessment ratings. We did not find that AGREE II ratings were
sensitive to the CPG’s strength of underlying evidence. These findings carry important
implications for emergency medicine clinical guideline developers, the broader clinical
practice guideline community, and physicians using these guidelines to provide
emergency care.
Discussion of primary results
ACEP Clinical Policies showed highest quality in Scope and Purpose. Compared
to prior published research, our finding that this domain scored highest (mean rating
90%) and varied least (CV 3.1%) is not surprising. For example, studies utilizing the
AGREE II instrument to evaluate CPGs for hepatocellular carcinoma (37), spinal
conditions (23), and intracranial aneurysms (36) similarly reported Scope and Purpose as
the highest scoring domain. The quality elements of the Scope of Purpose domain
(objectives, clinical questions, and target population) are inherently addressed in ACEP
Clinical Policies due to ACEP’s standardized and formulaic guideline development
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process centered on clear clinical questions.
ACEP Clinical Policies also showed strengths in Rigor of Development (mean
rating 78%) and Clarity of Presentation (mean rating 75%). The aim of the Rigor of
Development domain is to evaluate whether the methods and guideline development
process are thorough and transparent, specifically in searching for evidence, assessing the
quality of evidence, and formulating recommendations. Prior research has shown that
many guidelines in other specialties lack explanation of the quality of underlying
evidence or strength of recommendations (36). ACEP Clinical Policies clearly present the
level of each recommendation and provide explanation of the CPG’s underlying evidence.
This is a strength that demonstrates appropriate methodological transparency in ACEP’s
guideline development process. However, while ACEP Clinical Policies thoroughly
describe the process of searching for evidence, they could be improved with a more direct
explanation or specific examples of how the evidence is linked to each specific
recommendation. For Clarity of Presentation, we found that ACEP Clinical Policies use
clear language, are formatted logically, provide specific recommendations, and consider
alternative options for management. Overall, high mean ratings in Scope and Purpose,
Rigor of Development, and Clarity of Presentation indicate strong technical quality and
clear delivery of information in ACEP Clinical Policies.
The lowest scoring domain across ACEP Clinical Policies was Applicability. The
quality elements of Applicability include facilitators and barriers to CPG application,
resource implications of the recommendations, and monitoring or audit criteria. Other
studies have shown similar weakness in the Applicability domain, and thus it is
reasonable that this domain had both the lowest score (mean rating 35%) and highest
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variability (CV 0.16). For example, Wang et al. (37) evaluated 40 guidelines related to
liver cancer and found that most guidelines failed to address tools required for facilitating
guideline implementation, resulting in an average Applicability domain rating of 16%
using the AGREE II instrument. Low scores in Applicability could reflect a belief that
guideline development and guideline implementation are separate activities. Guideline
developers may feel that the organizational barriers and cost implications are better
discussed among local administrators who can make more individualized decisions based
on local settings or institutional priorities. This seems especially true in the practice of
emergency medicine, which is greatly affected by practice location, available resources,
and patient demographics. Therefore, statements about appropriate implementation of
recommendations and resource implications are difficult to make universally, so the low
mean rating and high variability for this domain across the 20 CPGs in this study were
expected. The Applicability domain ratings for these ACEP Clinical Policies could be
improved with clearer monitoring criteria and discussion of both the resource
implications and barriers to guideline implementation. Given the resources and time
required to develop these guidelines, it is understandable that frequent revisions are
infeasible; however, regular updates in a less formal manner, such as an official online
forum or mobile application could be utilized to disseminate new influential evidence that
becomes available. This approach has been taken by developers of Guideline Central
(available at https://www.guidelinecentral.com/mobile-and-web-apps/), a digital resource
and mobile application that provides official recommendations from various respected
medical associations and is frequently updated to reflect the latest content.
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There were two domains that received mixed ratings: Stakeholder Involvement
(mean rating 53%) and Editorial Independence (mean rating 69%). While ACEP Clinical
Policies are developed in collaboration with individuals from multiple relevant
professional groups, they do not explicitly mention seeking the views and preferences of
the target population (38). This is a common weakness among CPGs in the U.S.:
Armstrong and Bloom (38) recently reviewed 101 guideline development organizations
and reported that only 8% consistently require patient and public involvement. Given the
increasing emphasis on patient partnership in research and policy making, U.S. guideline
development organizations should look to examples such as the National Institute for
Clinical Excellence in the U.K. for models on including patient representation in
guideline development (5, 38). Editorial Independence assesses whether the CPG’s
development was influenced by funding sources or interests of the authors to determine
whether recommendations are based on the best-available evidence alone or affected by
those with conflicts of interest. Editorial independence has been a long-standing source of
controversy for CPGs in several specialties. In 2004, new cholesterol guidelines greatly
expanded the number of people recommended for treatment, and yet the vast majority of
guideline authors were found to have relationships with manufacturers of cholesterol
lowering drugs (39). Another survey found that most chairs and co-chairs of clinical
policy committees had financial conflicts of interest (21). The risks of poor editorial
independence are numerous. Guidelines disseminated by respected organizations can be
utilized to create institutional protocols, develop quality measures, inform insurance
coverage decisions, and influence the selection of medications on drug formularies (17):
the quality and reliability of all of these are threatened by biased guidelines. Further,
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CPGs can be viewed as reliable authority in malpractice lawsuits, and this may place
pressure on physicians to follow guideline recommendations even if they have concern
about industry influence over guideline development. Our results for the Editorial
Independence domain (mean rating 69%) indicate that ACEP Clinical Policies could
improve in this area but are relatively strong in this domain compared to other guidelines
(7, 19, 20, 24-27). To improve the strength of Editorial Independence, more explicit and
thorough disclosure about both financial and intellectual conflicts of interest among
guideline developers should be included. Further, explanation should be provided about
how these conflicts of interest were managed and accounted for (i.e., whether certain
competing interests excluded members from specific aspects of guideline development).
In addition to the domain level ratings, the mean Overall Assessment rating for all
20 Clinical Policies was quite high at 69%. Of note, however, the Overall Assessment
component is a new addition since the original AGREE instrument and warrants
consideration of its nuances. Unlike the 23 appraisal items within the six domains that
have detailed criteria to guide appraisers, the Overall Assessment does not include
specific directions, and is the most subjective component of the AGREE II instrument.
This dichotomy of including both formulaic and subjective elements may be confusing
for users and those interpreting the instrument’s output. AGREE II developers could offer
advice about how to arrive at an Overall Assessment rating, perhaps with suggestions for
weighing the six domains or by providing other relevant criteria. If, however, AGREE II
developers believe it is important to maintain some area for flexibility and subjectivity
that transcends specific criteria, it should at least be made clear to those interpreting
AGREE II scores that Overall Assessment ratings are subjective and distinct from the
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item-defined domain ratings. Overall, these authors believe there is value to this
subjective component of the AGREE II instrument, and our results indicate the global
strength of the ACEP Clinical Policy development methodology.
Most ACEP Clinical Policies were recommended for clinical use by our five
appraisers, which supports our opinion that ACEP Clinical Policies are of high quality.
There were, however, four guidelines that some appraisers did not recommend for
clinical use. It is noteworthy that the guidelines that received any “no” responses for
recommendation for clinical use also had the lowest Overall Assessment ratings,
indicating agreement between these two modes of assessment.
Our results extend the findings of two other recent studies that utilized the
AGREE II instrument to evaluate individual ACEP Clinical Policies, revealing similar
strengths and weaknesses. First, Pak et al. (40) assessed three guidelines on management
of hypertension, including one published by ACEP. Compared to our results for that
ACEP Clinical Policy, Pak et al. reported a similar average domain rating (67% vs. our
result of 65%) and similar rankings for domain scores, with Scope and Purpose and Rigor
of Development scoring highest and Applicability scoring lowest. The similar average
domain rating and domain ranking suggest good agreement and consistency between two
different groups of appraisers evaluating the same ACEP Clinical Policy.
Second, Patel et al. (27) evaluated 24 CPGs related to management of traumatic
brain injury, including one ACEP Clinical Policy. They reported mean domain and
Overall Assessment ratings similar to those in our study, again suggesting consistency
and reliability with the AGREE II instrument between two different appraisal groups. An
older study, Tavender et al. (41), utilized the original AGREE instrument in 2010 to
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evaluate the same ACEP Clinical Policy on traumatic brain injury. Tavender et al.’s
ratings were consistently lower than those in our study, but the order of domain
performance, from highest to lowest, was identical to ours, suggesting that Tavender et
al.’s appraisers were consistently more strict but identified similar areas of strength and
weakness in the Clinical Policy.
Inter-rater reliability
Our results of low intraclass coefficients suggest poor inter-rater reliability. The
ICC in this study can be explained by the low variance of ratings in comparison to the
total possible variance of a seven-item scale. While a modestly higher ICC may be
achieved with a larger number of guidelines or reviewers, the effect of a larger sample
size on the ICC is not likely to be substantial as this study already exceeded the
recommended number of reviewers by the AGREE II developers. Given the ICC’s
sensitivity to low score variability between reviewers in each domain, an alternative
approach to measuring agreement between reviewers may be more appropriate for
examining broad consistency between reviewers (such as whether reviewers consistently
rate each domain above or below an average as opposed to a measure of scale).
Discussion of secondary analysis
We conducted several secondary analyses to explore trends and underlying causes
of the variation in AGREE II domain and Overall Assessment ratings.
Trends in AGREE II ratings over time
We did not find that domain or Overall Assessment ratings improved over the
prior decade or after recent methodological updates. As discussed previously, concern
about conflict of interest in the 2013 tPA Clinical Policy generated substantial
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controversy and sparked ACEP’s methodological updates that became effective in 2015.
However, our study using the AGREE II instrument did not find significant improvement
in the editorial independence of ACEP’s Clinical Policy development process since these
updates.
Relationships between domain ratings and overall assessment ratings
To better understand how appraisers may arrive at Overall Assessment ratings, we
examined whether particular domain ratings were correlated with Overall Assessment
ratings. Our findings that Rigor of Development and Clarity of Presentation were most
strongly associated with Overall Assessment do not imply that these two domains are
predictive of the Overall Assessment rating, but rather suggest that strong performance
on these two domains may be influential on the appraiser’s overall impression of the
CPG’s quality. Similarly, Hoffmann-Esser et al. (42) evaluated various aspects of the
AGREE II Overall Assessment ratings in 1453 guidelines and found that Rigor of
Development had the strongest correlation with Overall Assessment rating. This likely
reflects that clinicians highly value the thoroughness of the literature search and final
structure of a guideline in evaluating overall CPG quality.
Strength of underlying evidence and level of recommendations
We found that AGREE II ratings were not sensitive to the proportion of
underlying Class III evidence or proportion of Level C recommendations within the
CPGs, and this is consistent with the design of the AGREE II instrument. While AGREE
II evaluates whether the guideline reports the quality of underlying evidence and presents
the recommendations clearly, the instrument does not consider the strength of evidence or
recommendations in formulating its quality assessment of the CPG. In other words, the
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AGREE II criteria are blind to the quality of evidence supporting the guideline. This is
both a strength and weakness of the AGREE II instrument. One benefit is that the
AGREE II instrument specifically examines elements performed by, and in the control of,
guideline authors, and the instrument is less sensitive to factors beyond authors’ control
(i.e., amount of available literature or strength of scientific evidence). However, this
attribute is a weakness because AGREE II ratings do not necessarily indicate whether the
recommendations within a CPG can be followed reliably. It is possible that a CPG can
score very high on most criteria of AGREE II and yet have no reliable benefit in clinical
practice.
Implications for AGREE II instrument developers and users
Overall, our appraisers found the AGREE II instrument to be well structured, user
friendly, thorough, and useful in assessing guideline quality. Notable strengths include its
informative online training module, detailed instructions with examples for scoring each
item, logical and comprehensive structure of items and domains, and an easy-to-use
online interface. A weakness of this instrument for those interested in implementing
recommendations into practice is its inability to evaluate the quality of evidence or
reliability of the CPG’s recommendations. This, however, is advantageous for guideline
authors who strictly seek to know if their development process is rigorous and transparent.
The current AGREE II reflects methodological processes and not necessarily content, and
so high AGREE II scores reflect the quality of reporting more than quality of evidence or
content. Including criteria that considers the strength of underlying evidence would
create a more comprehensive instrument that could provide physicians with more
confidence in implementing CPGs with high AGREE II ratings.
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Finally, while the AGREE II instrument has been thoroughly validated and shown
to be reliable, evidence is still lacking about whether high AGREE II ratings translate to
substantial benefits for guidelines’ stakeholders, which include institutions, guideline
developers, administrators, physicians, and patients. For example, in the previously
discussed Pak et al. study on guidelines for hypertension, ACEP’s Clinical Policy had
higher AGREE II ratings than the CPG published by the European Society of
Hypertension (ESH). Despite the ACEP Clinical Policy’s relatively strong performance
according to AGREE II domain ratings, the authors of that study did not recommend
ACEP’s guideline for clinical use, while they did recommend the lower scoring CPG by
ESH. Those authors justified this by explaining that the ACEP Clinical Policy did not
address management of hypertensive emergency, indicating that AGREE II ratings and
clinical usefulness are not necessarily related. Future research should explore how
utilization of the AGREE II instrument can affect the implementation of CPGs,
knowledge translation, and clinical outcomes.
Implications for ACEP Clinical Policies development and use
Our study has identified specific strengths and weaknesses of ACEP Clinical
Policies. Even though addressing all issues of applicability may be infeasible or an
inefficient utilization of limited ACEP resources, some additional consideration of
resource implications, barriers or facilitators for implementation, and monitoring or audit
criteria would improve these Clinical Policies within the current scope of development.
Future guidelines should at least inform users of the need to consider applicability issues
when implementing guideline recommendations. ACEP Clinical Policies could be also
improved with broader stakeholder involvement that includes representation from
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patients or target populations and more thorough disclosure about both financial and
intellectual conflicts of interest among guideline developers.

Limitations
There are limitations of this project that warrant discussion. While this study has
focused on guideline appraisal using the AGREE II instrument, it is worthwhile to
compare this instrument with the IOM’s standards of guideline trustworthiness in
“Clinical Practice Guidelines We Can Trust” (5). While some consider the IOM’s
standards to be more comprehensive than AGREE II (16, 17), the disadvantages to sole
utilization of the IOM’s standards are that they are not structured into a validated
instrument for easy use and they offer only an inflexible all-or-nothing definition of
guideline trustworthiness. The AGREE II instrument covers similar content as the IOM’s
standards in a more user-friendly structure and more realistically manages partial
adherence to its criteria and, thus, is best suited for the aims of this study.
Use of the AGREE II instrument also has potential for bias as appraisers become
more familiar with the instrument. Ratings performed initially may be affected by a
reviewer’s unfamiliarity with the instrument or scale. Later, reviewers may improve their
consistency, be influenced by their prior ratings, or alter their interpretation of the rating
scale. Thus, we aimed to minimize this potential bias by assigning each appraiser a
unique randomized order to perform appraisals. In addition, all appraisers were from the
same academic center, and this may result in an institutional bias. One analytic limitation
of this study approach is the risk of committing type 1 error when performing multiple
comparisons; thus, we accounted for this by implementing the Bonferroni correction
where appropriate. Based on the ICC calculation, there was low inter-rater reliability in
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this study, and this was likely due to a low variance of ratings in comparison to the total
possible variance of a seven-item scale. Future work should explore alternative statistical
methods for assessing the consistency of responses between reviewers. Finally, our
analysis was limited to clinical practice guidelines developed by ACEP and did not
include any guidelines published by other specialty societies, in other countries, or in
other languages; therefore, many emergency care guidelines housed within the
documents and writing of other specialties or organizations are absent from this work.

Conclusions
ACEP Clinical Policies demonstrate strengths and weaknesses based on validated
criteria provided by the AGREE II instrument. Guideline quality did not improve over
time or after ACEP methodological updates in 2015 and is not related to the quality of
underlying evidence. ACEP Clinical Policies can be improved by including patient
representation in the guideline development process, increasing editorial independence
and transparency, and addressing factors that influence the application of these guidelines
in clinical practice.
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Figure 1. Comparison of Publication Year and Overall Assessment Rating
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Figure 2. Comparison of Overall Assessment Rating and Either Proportion of Level C Recommendations (2A) or Proportion
of Class III Evidence (2B)
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Table I. American College of Emergency Physicians – Current Clinical Policies
ID
ACEP-1
ACEP-2
ACEP-3
ACEP-4
ACEP-5
ACEP-6
ACEP-7
ACEP-8
ACEP-9
ACEP-10
ACEP-11
ACEP-12
ACEP-13
ACEP-14
ACEP-15
ACEP-16
ACEP-17
ACEP-18
ACEP-19
ACEP-20

Title
Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department
Critical Issues in the Initial Evaluation and Management of Patients Presenting to the Emergency Department in Early Pregnancy
Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Acute Carbon
Monoxide Poisoning
Critical Issues in the Evaluation of Adult Patients with Suspected Transient Ischemic Attack in the Emergency Department
Clinical Policy for Well-Appearing Infants and Children Younger Than 2 Years of Age Presenting to the Emergency Department
With Fever
Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department
Critical Issues in the Evaluation and Management of Adult Patients With Suspected Acute Nontraumatic Thoracic Aortic
Dissection
Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Seizures
Procedural Sedation and Analgesia in the Emergency Department
Critical Issues in the Evaluation and Management of Adult Patients in the Emergency Department with Asymptomatic Elevated
Blood Pressure
Clinical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department
Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Suspected
Pulmonary Embolism
Critical Issues in the Evaluation of Adult Patients Presenting to the Emergency Department With Acute Blunt Abdominal Trauma
Critical Issues in the Evaluation and Management of Emergency Department Patients With Suspected Appendicitis
Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Community-Acquired
Pneumonia
Neuroimaging and Decision making in Adult Mild Traumatic Brain Injury in the Acute Setting
Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute
Headache
Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Acute Heart
Failure Syndromes
Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Syncope
Emergency Department Management of Patients Needing Reperfusion Therapy for an ST-Segment Elevation Acute Myocardial
Infarction

Publication
Date
Apr 2017
Feb 2017
Jan 2017
Sep 2016
May 2016
Sep 2015
Jan 2015
Apr 2014
Feb 2014
Jul 2013
Oct 2012
Jun 2011
Apr 2011
Jan 2010
Nov 2009
Dec 2008
Oct 2008
May 2007
Apr 2007
Nov 2017
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Table II. Assessment of the Agree II Six Quality Domains and Overall Assessment of Clinical Policy
Guideline Title
Critical Issues in the Diagnosis
and Management of the Adult
Psychiatric Patient in the
Emergency Department
Critical Issues in the Initial
Evaluation and Management of
Patients Presenting to the
Emergency Department in Early
Pregnancy
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department with
Acute Carbon Monoxide
Poisoning
Critical Issues in the Evaluation
of Adult Patients with Suspected
Transient Ischemic Attack in the
Emergency Department
Clinical Policy for WellAppearing Infants and Children
Younger Than 2 Years of Age
Presenting to the Emergency
Department With Fever
Use of Intravenous Tissue
Plasminogen Activator for the
Management of Acute Ischemic
Stroke in the Emergency
Department

ID

Scope
and
Purpose

Stakeholder
Involvement

Rigor of
Development

Clarity of
Presentation

Applicability

Editorial
Independence

Overall
Assessment

ACEP1

84%

52%

78%

73%

42%

75%

70%

ACEP2

88%

54%

80%

74%

32%

72%

70%

ACEP3

86%

51%

76%

78%

32%

77%

63%

ACEP4

93%

48%

81%

76%

46%

72%

77%

ACEP5

96%

52%

81%

82%

38%

75%

80%

ACEP6

92%

46%

77%

72%

36%

73%

73%
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Table II. Assessment of the Agree II Six Quality Domains and Overall Assessment of Clinical Policy
Guideline Title
Critical Issues in the Evaluation
and Management of Adult
Patients With Suspected Acute
Nontraumatic Thoracic Aortic
Dissection
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department with
Seizures
Procedural Sedation and
Analgesia in the Emergency
Department
Critical Issues in the Evaluation
and Management of Adult
Patients in the Emergency
Department with Asymptomatic
Elevated Blood Pressure
Clinical Issues in the Prescribing
of Opioids for Adult Patients in
the Emergency Department
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department With
Suspected Pulmonary Embolism
Critical Issues in the Evaluation
of Adult Patients Presenting to
the Emergency Department With
Acute Blunt Abdominal Trauma

ID

Scope
and
Purpose

Stakeholder
Involvement

Rigor of
Development

Clarity of
Presentation

Applicability

Editorial
Independence

Overall
Assessment

ACEP7

91%

51%

80%

73%

36%

77%

70%

ACEP8

90%

51%

78%

76%

27%

62%

67%

ACEP9

92%

58%

82%

77%

35%

62%

70%

ACEP10

90%

49%

74%

69%

33%

77%

50%

ACEP11

90%

63%

75%

72%

36%

67%

53%

ACEP12

91%

51%

77%

79%

33%

73%

73%

ACEP13

88%

52%

77%

78%

32%

68%

70%
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Table II. Assessment of the Agree II Six Quality Domains and Overall Assessment of Clinical Policy
Guideline Title
Critical Issues in the Evaluation
and Management of Emergency
Department Patients With
Suspected Appendicitis
Critical Issues in the
Management of Adult Patients
Presenting to the Emergency
Department With CommunityAcquired Pneumonia
Neuroimaging and
Decisionmaking in Adult Mild
Traumatic Brain Injury in the
Acute Setting
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department With
Acute Headache
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department with
Acute Heart Failure Syndromes
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department with
Syncope
Emergency Department
Management of Patients
Needing Reperfusion Therapy

ID

Scope
and
Purpose

Stakeholder
Involvement

Rigor of
Development

Clarity of
Presentation

Applicability

Editorial
Independence

Overall
Assessment

ACEP14

87%

51%

73%

59%

29%

65%

50%

ACEP15

92%

56%

77%

76%

37%

68%

70%

ACEP16

93%

58%

78%

82%

44%

72%

83%

ACEP17

89%

52%

75%

80%

36%

63%

67%

ACEP18

91%

52%

75%

77%

27%

58%

73%

ACEP19

90%

53%

76%

73%

25%

37%

70%

ACEP20

91%

60%

82%

81%

43%

68%

80%
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Table II. Assessment of the Agree II Six Quality Domains and Overall Assessment of Clinical Policy
Guideline Title

ID

Scope
and
Purpose

Stakeholder
Involvement

Rigor of
Development

Clarity of
Presentation

Applicability

Editorial
Independence

Overall
Assessment

90 ± 2.8

53 ± 4.2

78 ± 2.7

75 ± 5.2

35 ± 5.7

68 ± 9.2

69 ± 9.1

0.03

0.08

0.03

0.07

0.16

0.14

0.13

84 - 96

46 - 63

73 - 82

59 - 82

25 - 46

37 - 77

50 – 83

for an ST-Segment Elevation
Acute Myocardial Infarction
Mean ± SD
Coefficient of Variation (CV)
Range
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Table III. Appraiser Recommendation for Clinical Policy Use and Overall Assessment
Five Appraisers

Guideline
ID

Guideline Title
Yes

Yes With
Modifications

No

Overall
Assessment

ACEP-1

Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in
the Emergency Department

3

2

0

70%

ACEP-2

Critical Issues in the Initial Evaluation and Management of Patients Presenting to
the Emergency Department in Early Pregnancy

3

2

0

70%

ACEP-3

Critical Issues in the Evaluation and Management of Adult Patients Presenting to
the Emergency Department with Acute Carbon Monoxide Poisoning

3

1

1

63%

ACEP-4

Critical Issues in the Evaluation of Adult Patients with Suspected Transient
Ischemic Attack in the Emergency Department

4

1

0

77%

ACEP-5

Clinical Policy for Well-Appearing Infants and Children Younger Than 2 Years of
Age Presenting to the Emergency Department With Fever

4

1

0

80%

ACEP-6

Use of Intravenous Tissue Plasminogen Activator for the Management of Acute
Ischemic Stroke in the Emergency Department

2

3

0

73%

ACEP-7

Critical Issues in the Evaluation and Management of Adult Patients With Suspected
Acute Nontraumatic Thoracic Aortic Dissection

4

1

0

70%

ACEP-8

Critical Issues in the Evaluation and Management of Adult Patients Presenting to
the Emergency Department with Seizures

3

2

0

67%

ACEP-9

Procedural Sedation and Analgesia in the Emergency Department

4

1

0

70%

ACEP-10

Critical Issues in the Evaluation and Management of Adult Patients in the
Emergency Department with Asymptomatic Elevated Blood Pressure

2

1

2

50%

ACEP-11

Clinical Issues in the Prescribing of Opioids for Adult Patients in the Emergency
Department

1

2

2

53%
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Table III. Appraiser Recommendation for Clinical Policy Use and Overall Assessment
Guideline
ID

Five Appraisers
Yes

Yes With
Modifications

No

Overall
Assessment

Guideline Title

ACEP-12

Critical Issues in the Evaluation and Management of Adult Patients Presenting to
the Emergency Department With Suspected Pulmonary Embolism

4

1

0

73%

ACEP-13

Critical Issues in the Evaluation of Adult Patients Presenting to the Emergency
Department With Acute Blunt Abdominal Trauma

4

1

0

70%

ACEP-14

Critical Issues in the Evaluation and Management of Emergency Department
Patients With Suspected Appendicitis
Critical Issues in the Management of Adult Patients Presenting to the Emergency
Department With Community-Acquired Pneumonia
Neuroimaging and Decisionmaking in Adult Mild Traumatic Brain Injury in the
Acute Setting
Critical Issues in the Evaluation and Management of Adult Patients Presenting to
the Emergency Department With Acute Headache
Critical Issues in the Evaluation and Management of Adult Patients Presenting to
the Emergency Department with Acute Heart Failure Syndromes
Critical Issues in the Evaluation and Management of Adult Patients Presenting to
the Emergency Department with Syncope
Emergency Department Management of Patients Needing Reperfusion Therapy for
an ST-Segment Elevation Acute Myocardial Infarction
Five appraisers of 20 Guidelines
(100 recommendations)

1

3

1

50%

4

1

0

70%

4

1

0

83%

2

3

0

67%

4

1

0

73%

4

1

0

70%

4

1

0

80%

64/100
(64%)

30/100
(30%)

6/100
(6%)

ACEP-15
ACEP-16
ACEP-17
ACEP-18
ACEP-19
ACEP-20
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Table IV. Domain Ratings Before and After ACEP Clinical Policy Methodology Updates
AGREE II Domain
Pre-Sept 2015 Rating
Post-Sept 2015 Rating
p-valueA
Scope and Purpose
90%
90%
p = 0.67
Stakeholder Involvement
53%
53%
p = 0.94
Rigor of Development
77%
80%
p = 0.02
Clarity of Presentation
74%
77%
p = 0.18
Applicability
33%
38%
p = 0.09
Editorial Independence
66%
73%
p = 0.03
AStatistical significance was defined as p < 0.008 using the Bonferroni correction to account for
multiple comparisons
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Table V. Correlation Table Comparing the Six AGREE II Domains and Overall Assessment
Scope
Stakeholder
Rigor of
Clarity of
Editorial
Overall
Variable
and
Applicability
Involvement Development Presentation
Independence Assessment
Purpose
1
Scope and Purpose
Stakeholder
0.09
1
Involvement
0.43
0.20
1
Rigor of Development
0.42
0.25
0.52
1
Clarity of Presentation
0.28
0.21
0.53
0.36
1
Applicability
Editorial
0.01
0.19
0.21
0.08
0.54
1
Independence
0.70
0.77
0.51
0.05
0.46
0.01
1
Overall Assessment
A(p = 0.001)
A(p= 0.0001)
AStatistical significance was defined as p < 0.007 using the Bonferroni correction to account for multiple comparisons.
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Table VI(a). Clinical Policy Recommendations Levels, Classes of Evidence, and AGREE II Overall Assessment Rating
Policy
ID

ACEP20

ACEP1

ACEP2

ACEP3

ACEP4

ACEP5

Policy Title
Emergency Department
Management of Patients Needing
Reperfusion Therapy for Acute
ST-Segment Elevation
Myocardial Infarction
Critical Issues in the Diagnosis
and Management of the Adult
Psychiatric Patient in the
Emergency Department
Critical Issues in the Initial
Evaluation and Management of
Patients Presenting to the
Emergency Department in Early
Pregnancy
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department with
Acute Carbon Monoxide
Poisoning
Critical Issues in the Evaluation of
Adult Patients with Suspected
Transient Ischemic Attack in the
Emergency Department
Clinical Policy for WellAppearing Infants and Children
Younger Than 2 Years of Age
Presenting to the Emergency
Department With Fever

Recommendation Level
Level Level
Level
A
B
C

Class of Evidence
Class Class Class
I
II
III

Date of
Publication

Number of
Recommendations

Overall
Assessment

Nov 2017

4

0

2

2

0

2

7

80%

Apr 2017

4

0

0

4

0

0

6

70%

Feb 2017

3

0

2

1

0

10

10

63%

Jan 2017

3

0

3

0

0

6

8

77%

Sep 2016

4

0

2

2

0

18

45

80%

May 2016

6

0

2

4

0

3

19

73%
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Table VI(a). Clinical Policy Recommendations Levels, Classes of Evidence, and AGREE II Overall Assessment Rating
Policy
ID

ACEP6

ACEP7

ACEP8

ACEP9

ACEP10

ACEP11

ACEP12

Policy Title
Use of Intravenous Tissue
Plasminogen Activator for the
Management of Acute Ischemic
Stroke in the Emergency
Department
Critical Issues in the Evaluation
and Management of Adult
Patients With Suspected Acute
Nontraumatic Thoracic Aortic
Dissection
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department with
Seizures
Procedural Sedation and
Analgesia in the Emergency
Department
Critical Issues in the Evaluation
and Management of Adult
Patients in the Emergency
Department with Asymptomatic
Elevated Blood Pressure
Clinical Issues in the Prescribing
of Opioids for Adult Patients in
the Emergency Department
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department With
Suspected Pulmonary Embolism

Recommendation Level
Level Level
Level
A
B
C

Class of Evidence
Class Class Class
I
II
III

Date of
Publication

Number of
Recommendations

Sep 2015

2

0

2

2

1

6

71

73%

Jan 2015

6

0

2

4

2

3

23

70%

April 2014

6

1

1

4

1

3

32

67%

Feb 2014

6

1

3

2

2

10

16

70%

Jul 2013

2

0

0

2

0

2

4

50%

Oct 2012

5

0

1

4

1

4

15

53%

Jun 2011

10

1

5

4

9

38

75

73%

Overall
Assessment
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Table VI(a). Clinical Policy Recommendations Levels, Classes of Evidence, and AGREE II Overall Assessment Rating
Policy
ID
ACEP13

ACEP14

ACEP15

ACEP16

ACEP17

ACEP18

ACEP19

Policy Title
Critical Issues in the Evaluation of
Adult Patients Presenting to the
Emergency Department With
Acute Blunt Abdominal Trauma
Critical Issues in the Evaluation
and Management of Emergency
Department Patients With
Suspected Appendicitis
Critical Issues in the Management
of Adult Patients Presenting to the
Emergency Department With
Community-Acquired Pneumonia
Neuroimaging and
Decisionmaking in Adult Mild
Traumatic Brain Injury in the
Acute Setting
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department With
Acute Headache
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department with
Acute Heart Failure Syndromes
Critical Issues in the Evaluation
and Management of Adult
Patients Presenting to the
Emergency Department with
Syncope

Recommendation Level
Level Level
Level
A
B
C

Class of Evidence
Class Class Class
I
II
III

Date of
Publication

Number of
Recommendations

Apr 2011

6

0

3

3

1

7

7

70%

Jan 2010

4

0

3

1

9

21

35

50%

Nov 2009

4

0

2

2

0

10

20

70%

Dec 2008

5

1

2

2

4

15

24

83%

Oct 2008

6

0

3

3

1

10

32

67%

May 2007

7

0

4

3

5

34

31

73%

Apr 2007

5

2

2

1

4

8

10

70%

Overall
Assessment
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Table VI (b). Description of CPG Level Recommendation and Classification of Literature/EvidenceA
Level A Recommendation:
Generally accepted principles for patient
care that reflect a high degree of clinical
certainty (e.g., based on evidence from 1 or
more Class of Evidence I or multiple Class
of Evidence II studies)

Level B Recommendation:
Recommendation for patient care that may
identify a particular strategy or range of
strategies that reflect moderate clinical
certainty (e.g., based on evidence from 1 or
more Class of Evidence II studies or strong
consensus of Class of Evidence III studies)

Level C Recommendations:
Recommendations for patient care
that are based on evidence from
Class of Evidence III studies or in
the absence of any adequate
published literature, based on expert
consensus

Literature/Evidence Classification Schema
Design
Class

Therapy

Diagnosis

Prognosis

Randomized, controlled trial or
Prospective cohort using a criterion standard Population prospective cohort or
meta-analysis of randomized trials or meta-analysis of prospective studies
meta-analysis of prospective studies
Nonrandomized trial
Retrospective observational
Retrospective cohort. Case control
II
Case series
Case series
Case series
III
AThe recommendation levels and Design Class (I, II,III) are from ACEP Clinical Policy Development Process
https://www.acep.org/Clinical---Practice-Management/ACEP-Clinical-Policies-DevelopmentProcess/#sm.00000nl048nlvdoawtf22kfngb0xo
The Design Class descriptions are found in Appendix A of the Clinical Policies
I
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Appendix
Appendix I: The AGREE II Instrument
Domain 1. Scope and Purpose is concerned with the overall aim of the guideline, the specific health questions and the target population (items 13).
1) Objectives(s) – The overall objectives and guidelines is (are) specifically described
2) Question(s) – The health question(s) is (are) specifically described
3) Population – (patients, public, etc) to whom the guideline is meant to apply is specifically described
Domain 2. Stakeholder Involvement focuses on the extent to which the guideline was developed by the appropriate stakeholders and represents
the views of its intended users (items 4 -6).
4) Guidelines Group – the guideline development group includes individuals from all relevant professional groups
5) Patient Preferences – The view / preferences of the target population (patients, public, etc) have been sought
6) Target – The target users of the guideline are clearly defined
Domain 3. Rigor of Development relates to the process used to gather and synthesize the evidence and the methods to formulate and update the
recommendations (items 7-14).
7) Systematic Methods – Systematic methods were used to search for evidence
8) Selection Criteria – The criteria for selecting the evidence are clearly described
9) Strength and Limitations – The strengths and limitations of the body of evidence are clearly described
10) Method of Recommendations – The methods for formulating the recommendations are clearly described
11) Benefits, Side Effects and Risks – These aspects have been considered in formulating the recommendations
12) Evidence Link – There is an explicit link between the recommendations and the supporting evidence
13) External Review – The guideline has been externally reviewed by experts prior to its publication
14) Update Procedures – A procedure for updating the guideline is provided
Domain 4. Clarity of Presentation deals with the language, structure, and format of the guideline (items 15-17).
15) Recommendation Specific - The recommendations are specific and unambiguous
16) Options for Management – Different options for management of the condition/health issue are clearly presented
17) Recommendations identifiable – Key recommendation are easily identifiable
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Domain 5. Applicability pertains to the likely barriers and facilitators to implementation, strategies to improve uptake, and resource implications
of applying the guideline (items 18-21).
18) Facilitators and Barriers – The guideline describes facilitators and barriers to its application
19) Tools – The guideline provides advice and/or tools on how the recommendation can be put into practice
20) Resource Implications – Potential resource implications of applying the recommendation have been considered
21) Monitoring/Audit Criteria – The guideline presents monitoring and/or auditing criteria.
Domain 6. Editorial Independence is concerned with the formulation of recommendations not being unduly biased with competing interests
(items 22-23).
22) Funding Body – The views of the funding body have not influenced the content of the guideline
23) Competing Interests – Competing interests of guideline group members have been recorded and addressed.
Overall Assessment includes the rating of the
• The overall quality of the guideline (1-7 scale)
• Whether the guideline would be recommended for use in practice (yes, yes with modification, or no)
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Appendix II
AGREE II Domains and Overall Assessment Ratings by AZ
Scope and
Purpose
(21)A

Stake Holder
Involvement
(21)

Rigor of
Development
(56)

Clarity of
Presentation
(21)

Applicability
(28)

Editorial
Independence
(14)

Overall
Quality
(7)

1

20
(94%)B

14
(61%)

48
(83%)

17
(78%)

10
(25%)

10
(67%)

5
(67%)

2

20
(94%)

14
(61%)

48
(83%)

17
(78%)

7
(13%)

10
(67%)

5
(67%)

3

20
(94%)

13
(56%)

48
(83%)

17
(78%)

7
(13%)

10
(67%)

5
(67%)

4

20
(94%)

12
(50%)

48
(83%)

17
(78%)

9
(21%)

10
(67%)

5
(67%)

5

20
(94%)

14
(61%)

48
(83%)

17
(78%)

8
(17%)

10
(67%)

5
(67%)

6

20
(94%)

11
(44%)

45
(77%)

17
(78%)

9
(21%)

10
(67%)

5
(67%)

7

20
(94%)

13
(56%)

48
(83%)

17
(78%)

7
(13%)

10
(67%)

5
(67%)

8

20

14

46

17

8

10

5

Clinical Policy
ID
Critical Issues in the Diagnosis and
Management of the Adult Psychiatric
Patient in the Emergency Department
Critical Issues in the Initial Evaluation
and Management of Patients Presenting
to the Emergency Department in Early
Pregnancy
Critical Issues in the Evaluation and
Management of Adult Patients
Presenting to the Emergency
Department with Acute Carbon
Monoxide Poisoning
Critical Issues in the Evaluation of Adult
Patients with Suspected Transient
Ischemic Attack in the Emergency
Department
Clinical Policy for Well-Appearing
Infants and Children Younger Than 2
Years of Age Presenting to the
Emergency Department With Fever
Use of Intravenous Tissue Plasminogen
Activator for the Management of Acute
Ischemic Stroke in the Emergency
Department
Critical Issues in the Evaluation and
Management of Adult Patients With
Suspected Acute Nontraumatic Thoracic
Aortic Dissection
Critical Issues in the Evaluation and
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AGREE II Domains and Overall Assessment Ratings by AZ
Scope and
Purpose
(21)A
(94%)

Stake Holder
Involvement
(21)
(61%)

Rigor of
Development
(56)
(83%)

Clarity of
Presentation
(21)
(78%)

Applicability
(28)
(17%)

Editorial
Independence
(14)
(67%)

Overall
Quality
(7)
(67%)

9

20
(94%)

14
(61%)

46
(79%)

17
(78%)

8
(17%)

10
(67%)

5
(67%)

10

20
(94%)

13
(56%)

45
(77%)

17
(78%)

8
(17%)

10
(67%)

5
(67%)

11

20
(94%)

19
(89%

46
(79%)

17
(78%)

8
(17%)

12
(83%)

5
(67%)

12

20
(94%)

13
(56%)

46
(79%)

17
(78%)

6
(8%)

10
(67%)

5
(67%)

13

20
(94%)

13
(56%)

46
(79%)

17
(78%)

6
(8%)

10
(67%)

5
(67%)

14

20
(94%)

13
(56%)

46
(79%)

17
(78%)

7
(13%)

8
(50%)

5
(67%)

15

20
(94%)

15
(67%)

46
(79%)

17
(78%)

7
(13%)

8
(50%)

5
(67%)

16

20
(94%)

13
(56%)

44
(75%)

17
(78%)

7
(13%)

12
(83%)

5
(67%)

Clinical Policy
ID
Management of Adult Patients
Presenting to the Emergency
Department with Seizures
Procedural Sedation and Analgesia in
the Emergency Department
Critical Issues in the Evaluation and
Management of Adult Patients in the
Emergency Department with
Asymptomatic Elevated Blood Pressure
Clinical Issues in the Prescribing of
Opioids for Adult Patients in the
Emergency Department
Critical Issues in the Evaluation and
Management of Adult Patients
Presenting to the Emergency
Department With Suspected Pulmonary
Embolism
Critical Issues in the Evaluation of Adult
Patients Presenting to the Emergency
Department With Acute Blunt
Abdominal Trauma
Critical Issues in the Evaluation and
Management of Emergency Department
Patients With Suspected Appendicitis
Critical Issues in the Management of
Adult Patients Presenting to the
Emergency Department With
Community-Acquired Pneumonia
Neuroimaging and Decision making in
Adult Mild Traumatic Brain Injury in
the Acute Setting
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AGREE II Domains and Overall Assessment Ratings by AZ
Clinical Policy

Scope and
Purpose
(21)A

Stake Holder
Involvement
(21)

Rigor of
Development
(56)

Clarity of
Presentation
(21)

Applicability
(28)

Editorial
Independence
(14)

Overall
Quality
(7)

ID
Critical Issues in the Evaluation and
Management of Adult Patients
20
13
46
18
7
8
5
17
Presenting to the Emergency
(94%)
(56%)
(79%)
(83%)
(13%)
(50%)
(67%)
Department With Acute Headache
Critical Issues in the Evaluation and
Management of Adult Patients
20
13
46
17
6
8
5
Presenting to the Emergency
18
(94%)
(56%)
(79%)
(78%)
(8%)
(50%)
(67%)
Department with Acute Heart Failure
Syndromes
Critical Issues in the Evaluation and
Management of Adult Patients
20
13
46
17
5
4
5
19
Presenting to the Emergency
(94%)
(56%)
(79%)
(78%)
(4%)
(17%)
(67%)
Department with Syncope
Emergency Department Management of
Patients Needing Reperfusion Therapy
20
14
46
17
10
10
5
20
for an ST-Segment Elevation Acute
(94%)
(61%)
(79%)
(78%)
(25%)
(67%)
(67%)
Myocardial Infarction
Range 94 – 94%
50 – 89%
77 – 83%
78 – 83%
4 – 25%
17 – 83%
67 – 67%
A
Maximum Score for each AGREE II domain is in parentheses
B
Each domain and overall assessment score is standardized as a percentage according to the following formula recommended by AGREE II developers (AGREE
Next Steps Consortium, 2009, The AGREE II Instrument (Electronic version). http://www.agreetrust.org.):
(Obtained score – Minimum possible score) / (Maximum possible score – Minimum possible score) x 100

